Infinity Pharmaceuticals, Inc. Stock price

Equities

INFI.Q

US45665G3039

Biotechnology & Medical Research

End-of-day quote OTC Markets 07:00:00 2024-03-26 pm EDT 5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for Infinity Pharmaceuticals, Inc. -99.00% -99.96%
Sales 2021 1.86M Sales 2022 2.59M Capitalization 49.59M
Net income 2021 -45M Net income 2022 -44M EV / Sales 2021 91.8 x
Net cash position 2021 29.67M Net Debt 2022 11.04M EV / Sales 2022 23.4 x
P/E ratio 2021
-4.25 x
P/E ratio 2022
-1.11 x
Employees 30
Yield 2021 *
-
Yield 2022
-
Free-Float 97.27%
More Fundamentals * Assessed data
Dynamic Chart
1 week-99.00%
3 months-99.95%
6 months-99.99%
Current year-99.96%
More quotes
1 month
0.00
Extreme 0
0.00
Current year
0.00
Extreme 0
0.02
1 year
0.00
Extreme 0
0.26
3 years
0.00
Extreme 0
3.89
5 years
0.00
Extreme 0
5.98
10 years
0.00
Extreme 0
18.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 08-02-29
Corporate Officer/Principal - 17-09-30
Corporate Officer/Principal - -
Members of the board TitleAgeSince
Director/Board Member 83 06-08-31
Director/Board Member 71 12-03-11
Director/Board Member 75 18-03-31
More insiders
Date Price Change Volume
24-03-27 0.000001 0.00% 3,000
24-03-25 0.000001 0.00% 3,194
24-03-22 0.000001 -99.00% 2,748
24-03-20 0.0001 +900.00% 680

End-of-day quote OTC Markets, March 26, 2024

More quotes
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
  1. Stock
  2. Equities
  3. Stock Infinity Pharmaceuticals, Inc. - OTC Markets